WHO Propose Dolutegravir (DTG) As Favoured HIV Treatment Option


Following the analysis of the advantages and dangers ,The WHO approve the utilisation of the HIV drug DTG as a favoured first line and second line treatment for everybody plus expectant women and those women who expect to become pregnant in future.

Preliminary research had emphasised a feasible connection linking DTG and neural tube defects,these are birth defects of the brain, spine or spinal cord, in children born to mothers who took the drug during conception. This possible welfare concern recorded in May 2018, from a research in Botswana that discovered four cases of neural tube defects out of 426 women who conceived while taking DTG.

Following these findings, most countries suggested to women who were pregnant or wantd to conceive  to take (EFV), Efavirnz drug instead.

Latest  findings of two massive clinical trials measuring the potency and safeness of EFG and DTG in Africa have determined that neural tube defects are notably less than earlier studies tabled.

DTG is therefore highly recommended by WHO because it is efficient and simple to take and has registered very few side effects compared to other HIV drugs.DTG also has a high genetic barrier to resistance , meaning its highly unlikely for the virus to mutate and develop resistance to the drug.

EFV and other Nevirapines based  drugs have registered more cases of  resistance.

Given the findings, WHO has updated its guidelines and encourages countries to shift to DTG in order to achieve health policies.